$ASMB
Assembly Biosciences Inc Stock $asmb

$asmb Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415048978 Filed on August 13, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.490M	$2.490M	$1.410M
YoY Change	-66.26%	76.6%	8.46%
% of Gross Profit
Research & Development	$4.630M	$4.668M	$1.096M
YoY Change	26.09%	326.03%	-68.77%
% of Gross Profit
Depreciation & Amortization	$18.00K	$16.00K	$1.026K
YoY Change	1023.6%	1459.45%
% of Gross Profit
Operating Expenses	$4.630M	$4.668M	$1.096M
YoY Change	26.09%	326.03%	-68.77%
Operating Profit	-$7.122M	-$7.154M	-$2.506M
YoY Change	-35.58%	185.45%	-47.88%
Interest Expense	$500.0K	$210.0K	$40.00K
YoY Change	1150.0%	425.0%	-33.33%
% of Operating Profit
Other Income/Expense, Net	$504.3K	$211.2K
YoY Change	1333.38%
Pretax Income	-$6.620M	-$6.940M	-$2.470M
YoY Change	-39.93%	180.97%	-48.0%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$6.618M	-$6.943M	-$2.469M
YoY Change	-39.95%	181.16%	-48.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$384.7K	-$405.4K	-$525.5K
COMMON SHARES
Basic Shares Outstanding	17.19M shares	17.18M shares	23.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$65.80M	$70.70M	$21.30M
YoY Change	267.6%	231.92%	-36.42%
Cash & Equivalents	$36.40M	$53.52M	$21.32M
Short-Term Investments	$29.40M	$17.20M
Other Short-Term Assets	$705.3K	$605.2K	$171.6K
YoY Change	379.21%	252.75%	-3.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$66.50M	$71.33M	$21.75M
YoY Change	267.83%	228.0%	-35.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$156.5K	$174.0K	$7.399K
YoY Change	359.11%	2252.14%	-20.69%
Goodwill	$12.64M
YoY Change	0.0%
Intangibles	$29.00M
YoY Change	-3.77%
Long-Term Investments	$31.40M	$31.60M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$73.15M	$73.37M	$7.399K
YoY Change	72.88%	991579.58%	-20.69%
TOTAL ASSETS
Total Short-Term Assets	$66.50M	$71.33M	$21.75M
Total Long-Term Assets	$73.15M	$73.37M	$7.399K
Total Assets	$139.7M	$144.7M	$21.76M
YoY Change	131.24%	565.16%	-35.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.500M	$1.300M	$1.421M
YoY Change	50.0%	-8.54%	-33.32%
Accrued Expenses	$1.187M	$935.7K	$48.44K
YoY Change		1831.8%	-89.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.652M	$2.240M	$1.500M
YoY Change	152.77%	49.33%	-42.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$11.60M	$11.60M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.652M	$2.240M	$1.500M
Total Long-Term Liabilities	$11.60M	$11.60M	$0.00
Total Liabilities	$14.25M	$13.84M	$1.470M
YoY Change	8.03%	841.63%	-43.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$156.2M	-$149.6M
YoY Change	20.83%
Common Stock	$17.23K	$17.19K	$4.679K
YoY Change		267.39%	-76.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$125.4M	$130.9M	$20.29M
YoY Change
Total Liabilities & Shareholders Equity	$139.7M	$144.7M	$21.76M
YoY Change	131.24%	565.13%	-35.4%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$6.618M	-$6.943M	-$2.469M
YoY Change	-39.95%	181.16%	-48.04%
Depreciation, Depletion And Amortization	$18.00K	$16.00K	$1.026K
YoY Change	1023.6%	1459.45%
Cash From Operating Activities	-$5.180M	-$4.390M	-$2.320M
YoY Change	33.85%	89.22%	-31.36%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$20.00K	$0.00
YoY Change	-100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$12.19M	-$48.78M
YoY Change	-2490.2%
Cash From Investing Activities	-$12.19M	-$48.80M	$0.00
YoY Change	-2587.76%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	260.0K	10.64M	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-5.180M	-4.390M	-2.320M
Cash From Investing Activities	-12.19M	-48.80M	0.000
Cash From Financing Activities	260.0K	10.64M	0.000
Net Change In Cash	-17.11M	-42.55M	-2.320M
YoY Change	406.21%	1734.05%	-31.56%
FREE CASH FLOW
Cash From Operating Activities	-$5.180M	-$4.390M	-$2.320M
Capital Expenditures	$0.00	-$20.00K	$0.00
Free Cash Flow	-$5.180M	-$4.370M	-$2.320M
YoY Change	34.55%	88.36%	-31.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	605162	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	71332755	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	125284	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001426800
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17189906	shares
CY2014Q4	us-gaap	Assets Current AssetsCurrent	29216397	USD
	dei	Entity Registrant Name EntityRegistrantName	ASSEMBLY BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	ASMB
CY2014Q4	us-gaap	Assets Assets	71225193	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2239960	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1054021	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	11600000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	11600000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	13839960	USD
CY2014Q4	us-gaap	Liabilities Liabilities	12654021	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	17190	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14087624	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6539190	USD
	us-gaap	Depreciation Depreciation	30397	USD
	us-gaap	Depreciation Depreciation	2292	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5206024	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	567512	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8056007	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7505455	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47991	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2589	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48828775	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2589	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81311814	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1763104	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	24427032	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146420	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-135512072	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	174035	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156441	USD
CY2015Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1304295	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	280583892	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-149599696	USD
CY2014Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	907601	USD
CY2015Q2	us-gaap	Assets Assets	144707127	USD
CY2015Q2	us-gaap	Security Deposit SecurityDeposit	125084	USD
CY2014Q4	us-gaap	Security Deposit SecurityDeposit	115005	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	935665	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	194072572	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	10672	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8502188	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4069334	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14357123	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14357123	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6616295	USD
	us-gaap	Interest Income Other InterestIncomeOther	269499	USD
	us-gaap	Interest Income Other InterestIncomeOther	77105	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	269499	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	77105	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5744940	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27061268	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21316328	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	396694	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1193266	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	888459	USD
CY2014Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	0	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1095644	USD
CY2015Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7153905	USD
CY2014Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2506144	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7153905	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2506144	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	440	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4667754	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	25000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	479878	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	367803	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10672059	shares
CY2015Q2	us-gaap	Interest Income Other InterestIncomeOther	211234	USD
CY2014Q2	us-gaap	Interest Income Other InterestIncomeOther	36871	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2486151	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1410500	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17119488	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4704251	shares
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	6616295	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5854935	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2546961	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14164451	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4562384	shares
CY2014Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	23540	USD
CY2014Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	10350	USD
CY2014Q3	asmb	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill	12638136	USD
CY2014Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	42197995	USD
CY2014Q3	asmb	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expenses BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses	774899	USD
CY2014Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent	11600000	USD
CY2014Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	12374899	USD
CY2014Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	29823096	USD
CY2014Q3	us-gaap	Security Deposit SecurityDeposit	16606	USD
CY2014Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	29000000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	254673	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	206682	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80638	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	50241	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	519999	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	0	USD
CY2015Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	363039	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	52627	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	146420	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	246000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	266666	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1416034	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.78
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.20
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.05
	asmb	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue	0	USD
	asmb	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue	0	USD
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	18711282	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3237851	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3176519	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.26
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.91
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5187924	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39234231	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40666	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	486402	USD
CY2015Q2	asmb	Future Stock Based Compensation Expense Year Two FutureStockBasedCompensationExpenseYearTwo	2299663	USD
CY2015Q2	asmb	Future Stock Based Compensation Expense Year Three FutureStockBasedCompensationExpenseYearThree	446488	USD
CY2015Q2	asmb	Future Stock Based Compensation Expense Total FutureStockBasedCompensationExpenseTotal	5446774	USD
CY2015Q2	asmb	Future Stock Based Compensation Expense Remainder Of Fiscal Year FutureStockBasedCompensationExpenseRemainderOfFiscalYear	2605068	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3233295	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	762834	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2015Q2	us-gaap	Depreciation Depreciation	16493	USD
CY2014Q2	us-gaap	Depreciation Depreciation	1026	USD
CY2015Q2	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	0	USD
CY2015Q2	asmb	Business Acquisition Intangible Expected Tax Deductible Amount BusinessAcquisitionIntangibleExpectedTaxDeductibleAmount	0	USD
CY2014Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	4008848	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	621651	shares
CY2014Q3	asmb	Noncash Or Part Noncash Acquisition Share Exchange Business Combination NoncashOrPartNoncashAcquisitionShareExchangeBusinessCombination	29064148	USD
CY2014Q3	asmb	Noncash Or Part Noncash Acquisition Fair Value Of Vested Options And Restricted Stock NoncashOrPartNoncashAcquisitionFairValueOfVestedOptionsAndRestrictedStock	758948	USD
CY2014Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8.04
CY2014Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1959000	shares
CY2014Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5129	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0230	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2015Q2	asmb	Future Stock Based Compensation Expense Year Four FutureStockBasedCompensationExpenseYearFour	95555	USD
CY2014Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	509363	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2620244	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	312795	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5206024	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	567512	USD
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17189906	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17189906	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10672059	shares
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	asmb	Stock Issued During Period Value Common Stock Issued StockIssuedDuringPeriodValueCommonStockIssued	81014989	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	296825	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5206024	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-134219	USD
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	17209448	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2015Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	31437117	USD
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	USD
CY2015Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	73374372	USD
CY2014Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	42008796	USD
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11600000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11600000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-134219	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-134219	USD
CY2014Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7076890	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2469273	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14221843	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6539190	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-10079	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48780784	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	-134219	USD
	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	0	USD
	asmb	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	88	USD
	asmb	Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants	0	USD
CY2015Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	88293	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	93720	shares
	asmb	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	-134219	USD
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	48646565	USD
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	48780784	USD
	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	99000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	81014989	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1763104	USD
	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	296825	USD
	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	0	USD

Files In Submission

Name	View Source	Status
0001144204-15-048978-index-headers.html	Edgar Link	pending
0001144204-15-048978-index.html	Edgar Link	pending
0001144204-15-048978.txt	Edgar Link	pending
0001144204-15-048978-xbrl.zip	Edgar Link	pending
asmb-20150630.xml	Edgar Link	completed
asmb-20150630.xsd	Edgar Link	pending
asmb-20150630_cal.xml	Edgar Link	unprocessable
asmb-20150630_def.xml	Edgar Link	unprocessable
asmb-20150630_lab.xml	Edgar Link	unprocessable
asmb-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v417070_10q.htm	Edgar Link	pending
v417070_ex31-1.htm	Edgar Link	pending
v417070_ex31-2.htm	Edgar Link	pending
v417070_ex32-1.htm	Edgar Link	pending
v417070_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASMB
Assembly Biosciences Inc Stock $asmb

2015 Q3 Form 10-Q Financial Statement

#000114420415048978 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASMB Assembly Biosciences Inc Stock $asmb

2015 Q3 Form 10-Q Financial Statement

#000114420415048978 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASMB
Assembly Biosciences Inc Stock $asmb